Medical Devices Investors & VC Firms in Asia-Pacific

420 firms in this list, with a median first check of $500K. 82 of them lead rounds. Generated from verified public data and updated continuously.

Fund	FoxScore	HQ	Invests	Stage	Check	CRM
SO Solasta Ventures MJBCDYKG6 people	88🔒	Boston	US	Seed–Series B	—	+ Add to CRM
OV Overwater Ventures Llc IRAAAMCC7 people · Leads rounds	88🔒	Palo Alto	US	Pre-Seed–Seed	$400K – $2M	+ Add to CRM
SY Sycamore Ventures PGKYTTDL13 people	88🔒	Princeton	US	Growth–Late Stage	$5M – $20M	+ Add to CRM
LA Laerdal Million Lives Fund JTBSJJRP9 people	88🔒	San Francisco	US	Series A–Series B	$1M – $5M	+ Add to CRM
EI Eisai Innovation, Inc. YMR(PWKQ4 people	88🔒	Cambridge	US	Seed–Series A	$5M	+ Add to CRM
HM HM Venture Partners RLDHHHPL7 people · Leads rounds	88🔒	San Francisco	US	Seed–Growth	—	+ Add to CRM
TV TVM Capital HBKMLMMR10 people · Leads rounds	88🔒	Munich	DE	Seed–Late Stage	$1.1M – $16.2M	+ Add to CRM
PM PM Equity Partner DSSIWMAS11 people	88🔒	Lausanne	CH	Series A–Growth	$2M – $50M	+ Add to CRM
DI Diamond Edge Ventures CSNAHSKS10 people	88🔒	San Francisco	US	Seed–Series A	—	+ Add to CRM
IN Innvotec Ltd. NDSPSTMT4 people	88🔒	London	GB	Series A–Series B	$317.5K – $635K	+ Add to CRM
EL Elysia Capital MLSBFMLA7 people	88🔒	Turin	IT	—	—	+ Add to CRM
KA Kama Flow EBKTEBPO4 people	88🔒	Moscow	RU	Seed–Growth	—	+ Add to CRM
AR Artiman Ventures ASBWRRTD9 people	88🔒	Palo Alto	US	Seed–Series A	$2M – $6M	+ Add to CRM
AS Asia2G Capital AJAKIHJJ6 people	88🔒	Silicon Valley	US	Seed–Series A	—	+ Add to CRM
HB HB Ventures YTKYKHSZ9 people	88🔒	Vienna	AT	Growth	$1M – $10M	+ Add to CRM
LU Lumir Ventures ADJLDKGP6 people	88🔒	Tel Aviv-Yafo	IL	Growth	—	+ Add to CRM
IN InHealth Ventures IBBELBRB5 people · Leads rounds	88🔒	London	GB	Pre-Seed–Series A	$500K – $3M	+ Add to CRM
RO Rosetta Capital Ltd. JHKMMFDL8 people	88🔒	Oxford	GB	Growth–Late Stage	—	+ Add to CRM
FU Future Positive Capital SHATESPR4 people · Follows rounds	88🔒	—	FR	Pre-Seed–Series A	—	+ Add to CRM
AG Agate Medical Investments LP	88🔒	Tel-Aviv	IL	Growth–Late Stage	—	+ Add to CRM
SB SBI JI Innovation Advisory Ltd. HSVRVHDH6 people	88🔒	Tel Aviv-Yafo	IL	Seed–Series B	—	+ Add to CRM
ST Sturgeon Capital SHABCCKZ6 people	88🔒	London	GB	Pre-Seed–Series A	$500K – $2M	+ Add to CRM
WA Waarde Capital BPAHJLAS5 people	88🔒	Capellen	LU	Seed–Growth	$15M	+ Add to CRM
ET ETCapital MRJGDG3 people · Follows rounds	88🔒	Cambridge	GB	Seed–Series A	$100K – $952.5K	+ Add to CRM

Solasta Ventures

BostonSeed–Series B

MJBCDYKG6 people

Overwater Ventures Llc

Palo AltoPre-Seed–Seed$400K – $2M

IRAAAMCC7 people

Sycamore Ventures

PrincetonGrowth–Late Stage$5M – $20M

PGKYTTDL13 people

Laerdal Million Lives Fund

San FranciscoSeries A–Series B$1M – $5M

JTBSJJRP9 people

Eisai Innovation, Inc.

CambridgeSeed–Series A$5M

YMR(PWKQ4 people

HM Venture Partners

San FranciscoSeed–Growth

RLDHHHPL7 people

TVM Capital

MunichSeed–Late Stage$1.1M – $16.2M

HBKMLMMR10 people

PM Equity Partner

LausanneSeries A–Growth$2M – $50M

DSSIWMAS11 people

Diamond Edge Ventures

San FranciscoSeed–Series A

CSNAHSKS10 people

Innvotec Ltd.

LondonSeries A–Series B$317.5K – $635K

NDSPSTMT4 people

Elysia Capital

Turin

MLSBFMLA7 people

Kama Flow

MoscowSeed–Growth

EBKTEBPO4 people

Artiman Ventures

Palo AltoSeed–Series A$2M – $6M

ASBWRRTD9 people

Asia2G Capital

Silicon ValleySeed–Series A

AJAKIHJJ6 people

HB Ventures

ViennaGrowth$1M – $10M

YTKYKHSZ9 people

Lumir Ventures

Tel Aviv-YafoGrowth

ADJLDKGP6 people

InHealth Ventures

LondonPre-Seed–Series A$500K – $3M

IBBELBRB5 people

Rosetta Capital Ltd.

OxfordGrowth–Late Stage

JHKMMFDL8 people

Future Positive Capital

Pre-Seed–Series A

SHATESPR4 people

Agate Medical Investments LP

Tel-AvivGrowth–Late Stage

SBI JI Innovation Advisory Ltd.

Tel Aviv-YafoSeed–Series B

HSVRVHDH6 people

Sturgeon Capital

LondonPre-Seed–Series A$500K – $2M

SHABCCKZ6 people

Waarde Capital

CapellenSeed–Growth$15M

BPAHJLAS5 people

ETCapital

CambridgeSeed–Series A$100K – $952.5K

MRJGDG3 people

Data sourced from public filings and firms' own websites — see our methodology.